HomeProductsBioactive CompoundsNeuronal SignalingAChRCAS 249296-44-4
Chemical structure of CAS 249296-44-4

5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene

CAS No.249296-44-4
MDL No.N/A
MFC13H13N3
MW211.26
InChI KeyJQSHBVHOMNKWFT-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.249296-44-4
Product Name5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
IrritantIrritant
Environmental HazardEnvironmental Hazard
Signal Word:Warning
HCode:H302-H400-H410
PCode:P264-P270-P273-P301+P317-P330-P391-P501

Related Articles

Studies related to this compound and its mechanism of action

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.

Molecular pharmacology • Vol. 70, Issue 3 • 2006
PMID: 16766716DOI: 10.1124/mol.106.025130

Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 34, Issue 1 • 2006
PMID: 16221753DOI: 10.1124/dmd.105.006767

FDA speeds smoking cessation drug review.

JAMA • Vol. 295, Issue 6 • 2006
PMID: 16467225DOI: 10.1001/jama.295.6.614

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

JAMA • Vol. 296, Issue 1 • 2006
PMID: 16820547DOI: 10.1001/jama.296.1.56

Documentation

Similar Products